Pharmathen’s Post

Pharmathen Profile: Partners Group, an Investor Member of European Healthcare Investor Association (E.H.I.A.), acquired the company from BC Partners, another Investor Member. It is a leading developer and manufacturer of advanced drug delivery technologies that specialises in products that are so complex few others can make them. Its differentiated business model, along with its complex technology and experienced leadership team, sets it apart from other firms in the industry. WATCH the video below to hear how Partners Group has been working with Pharmathen's management team on key value creation initiatives to build the business. #privateequity #lifesciences Lauren Hasek Mark Hersee

UK Investment Summit 2024. A number of really large global companies invited and an announcement that £64bn pledged in investment. Great news! David Ricks, CEO of Eli Lilly, shared an interesting perspective on investing in the UK with Sean Farrington from BBC #WakeUpToMoney (Oct 15, 2024). In comparison to the US and Europe, the UK is a small market that is disconnected from the bigger market on it's door step. If the country wants investment from the likes of Eli Lilly, or better still, grow our own large company, the UK needs to encourage innovation and utilise real world studies of effects - in other words, be an incubator for ideas and have a willingness to test new approaches. This doesn't just relate to drugs, it stands for any industry. Time to get in front of the wave and help to shape the future rather than locked in to the pitting cycle of the undertow. David Crack FICA Patrick Smith Ayaan Mohamed Ali Michael Jakubiak Anthony H. #Innovation #RealWorldImpact #Investment #PilotProjects

📣 Go West, but is it Best? Unravelling the Nordic and US IPO Markets Join our panel of Biotech Leaders as they discuss: ·   The investor landscape in both regions, including the preferences, risk appetites, and trends shaping investment decisions in the biotech sector ·   What attracts investors in the Nordic market versus the US, and how can biotechs tailor their strategies accordingly? ·   How does the Nordic market's proximity to established European pharmaceutical hubs compare to the US market's global reach? What implications does this have for market penetration and collaboration opportunities? ·   Success stories, challenges faced, and lessons learned. What patterns emerge, and how can aspiring biotechs leverage this knowledge to optimize their IPO journey? 🎙 Hear from: · Lene Gerlach, Venture Partner, Hadean Ventures · Mathias Vinther, Principal, Forbion · Sonia Hallen, Investment Manager, Gilde Healthcare · Daniel Bolanowski, Portfolio Manager, Arctic Asset Management · Jonathan Dickson, Co-Head of EMEA, OTC Markets Group Find out more: https://lnkd.in/epmXiPwZ #LSXNordic #Biotech

𝙈&𝘼 𝙞𝙨 𝙝𝙚𝙧𝙚 𝙩𝙤 𝙨𝙩𝙖𝙮 We are very excited to have organised our first M&A and Funding in #LifeSciences Breakfast seminar with Pedersen & Partners this week.   With more than 60 decision makers from leading life sciences companies and scale-ups, this was a very successful event. A special thank you to our panel of high-calibre industry leaders: - Erik van den Berg - CEO, Memo Therapeutics AG  - Martijn Boot - Head of Legal, Brocacef - Dr. Jan Groen - CEO, Intravacc   - Jos Lunenberg - CEO, Surfix Diagnostics - Koenraad Wiedhaup - CEO, Leyden Labs 👉 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀:  - M&A, investment and fundraising dynamics: the market has returned to ‘normal’, and last year proved difficult for fundraising. There are funding opportunities to be found in the USA and Asia. In terms of deals, a shift is noticeable to companies that are in a later stage of their development. - External factors: the Netherlands may lose the ability to build innovations through bringing together (international) talent, (international) scientists and capital. - Regulatory constraints or threats affecting M&A and investments: the upcoming EU Pharma package will result in less access to new medicines for EU member states. - Exit Strategies & Market Climate: exit strategies should be clear at an early stage. The exit environment has improved and an increase in IPOs is expected in 2025 – 2026. Pieter van Duijvenvoorde // Ellen Gielen // Lydia van der Meulen #CMSlaw #mergersandacquisitions #funding

Maximizing Biotech Prospects via Knowledge and Practice At the foundation of Evergrowth BioHealthcare Capital's strategy, a proprietary investment approach called Integrated BioSci Investing was developed blending time-tested value and growth in investing with superior medical, scientific, and business expertise. The strategy highlights the edge of utilizing medical professionals and scientists with business knowledge for biotech stock selection. The fund targets businesses with sufficient market cap to successfully finance a drug's development, from research to commercialization. Smaller-cap companies with a $250 million to $2 billion capitalization are favored opportunities as they are uniquely poised for outsized growth while still enjoying sufficient liquidity unlike in the private markets. Invest in promising biotech opportunities by joining the Evergrowth Fund now! Take advantage of carefully selected investments designed for increased profits. Put your faith into the future's Pioneers! #Investment #Growth #Healthcare #Success

Taking on the role of a biotech CEO can be a daunting prospect, especially when it is your first time in the position. The journey in this industry is marked by a unique set of hurdles including scientific complexities, regulatory intricacies, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal, as they are well-positioned to empower and support first-time CEOs. V-Bio Ventures Senior Executive Shelley Margetson shares her insights on the benefits of a supportive relationship between a new biotech CEO and their Board Chair. https://lnkd.in/eACx4F3p #executive #biotech #VentureCapital

#ESG into business reality! Experience how the pharmaceutical business affects and is affected by the global transformation towards #Sustainability! Pharmathen's business day is an emersive journey to a more reasonable future!

Very happy to attend the Angelini Ventures 2024 Summit in #Rome. Interesting panel, companies presentations and talk. Getting the oppportunity to meet fellow investors is always a treat. Many thanks to Tanja Dowe and Paolo Di Giorgio for making it happen. #venturecapital #investment #digitalhealth #debiopharminnovationfund

Massachusetts PE news in February 📣 📍 Charlesbank Capital Partners takes over as the lead investor in Perspective Financial Group, succeeding CBPE Capital, signaling a strategic shift in ownership. 📍 Berkshire Partners-backed AHEAD acquires CDI, solidifying its position as a dominant force in the global digital platforms market with a combined entity valued at $3.7 billion. 📍 Sanofi Ventures backed Sudo Biosciences secures $147 million in Series B financing from notable investors like Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises, highlighting significant interest in its precision TYK2 inhibitors. 📍 Nordic Capital's acquisition of a majority stake in ActiveViam underscores the growing demand for data analytics in financial risk management, particularly amidst regulatory changes and the rise of big data. As part of the transaction, Guidepost Growth Equity, which first invested in ActiveViam in 2019, will sell all of its shares. 📍 Totango and Catalyst's merger, supported by Great Hill Partners, creates a robust customer growth platform, integrating enterprise customer success software with advanced analytics and AI capabilities to drive revenue growth from existing customers, reflecting a strategic response to evolving market demands #privateequity #massachusetts #mergersandacquisitions

Our Chief Business Officer Elaine Cheung will be speaking on a panel tomorrow at BIO Investor Forum in SF! 🧬🧬 While the rate of IPOs this year is slightly increased versus 2023, the market is still much less active since 2021 and hoping the Q3 interest rate cut of 0.5% sparks additional investor support. This session will examine how private company CEOs should be preparing now for the types of IPOs that will be best received by the public markets, along with the implications for any opportunistic secondary offerings, amid an era of heightened geopolitical and market volatility. Moderator Jakob Dupont, MD MA, Executive Partner - Sofinnova Investments Speakers Emily P. - MD, Principal - DCVC Bio Carolyn Ng - PhD, Partner and Managing Director - TPG Life Sciences Innovations Elaine Cheung, Chief Business Officer - Moonwalk Biosciences Pete Garcia, Chief Financial Officer - ALX Oncology Colin Walsh, PhD -Managing Director, Growth Equity, Goldman Sachs View the agenda: 👇👇 https://lnkd.in/dT3zhgkY